(Q36945112)

17 August 2017

1 reference

title

Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors (English)

1 reference

17 August 2017

1 reference

Carolyn F Deacon

1

0 references

publication date

1 September 2007

1 reference

Diabetes, Obesity and Metabolism

17 August 2017

published in

1 reference

17 August 2017

volume

9 Suppl 1

1 reference

17 August 2017

page(s)

23-31

1 reference

The role of gut hormones in glucose homeostasis

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Incretins, insulin secretion and Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

CD26: a surface protease involved in T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

The biology of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2007.00765.X

10.1111/J.1463-1326.2007.00765.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference